# Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

> **NCT01594398** · PHASE1 · COMPLETED · sponsor: **Syndax Pharmaceuticals** · enrollment: 14 (actual)

## Conditions studied

- Lung Cancer
- Non Small Cell Lung Cancer (NSCLC)
- Breast Cancer
- Estrogen Receptor Breast Cancer

## Interventions

- **DRUG:** entinostat
- **DRUG:** entinostat
- **DRUG:** Erlotinib
- **DRUG:** Erlotinib
- **DRUG:** Exemestane
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT01594398
- **Lead sponsor:** Syndax Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-04
- **Final completion:** 2014-05
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01594398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01594398, "Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01594398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*